Recap of Tuesday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Relmada Therapeutics’ (NASDAQ:RLMD) lead asset…
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Goldman Sachs Maintains Buy on Relmada Therapeutics, Lowers Price Target to $53
Goldman Sachs maintains Relmada Therapeutics (NASDAQ:RLMD) with a Buy and lowers the price target from $69 to $53.
Earnings Scheduled For March 23, 2022
Companies Reporting Before The Bell
• AYRO (NASDAQ:AYRO) is expected to report earnings for its fourth quarter.
Relmada Therapeutics’s Earnings Outlook
Relmada Therapeutics (NASDAQ:RLMD) is set to give its latest quarterly earnings report on Wednesday, 2022-03-23. Here's what investors need to know before the announcement.
Analysts estimate that Relmada Therapeutics will report an earnings per share (EPS) of $-1.83.
Relmada Aces REL-1017 Vs Ketamine Study For Abuse Potential
Relmada Therapeutics Inc (NASDAQ: RLMD) has
SVB Leerink Maintains Outperform on Relmada Therapeutics, Lowers Price Target to $42
SVB Leerink analyst Marc Goodman maintains Relmada Therapeutics (NASDAQ:RLMD) with a Outperform and lowers the price target from $50 to $42.
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Relmada Stock Falls After Equity Raise Of $150M To Fund Depression Candidate
Relmada Therapeutics Inc (NASDAQ:RLMD) priced an upsized underwritten public offering of 8.82 million shares at $17.00 per share, with gross…